ConductScience.org, home

Paper37698552

Recent Advances in Anti-Atherosclerosis and Potential Therapeutic Targets for Nanomaterial-Derived Drug Formulations.

Xiao Z and 11 others. Adv Sci (Weinh), 2023. Cited by 27 papers, by iCite.

Cite this record

ConductScience Library. Recent Advances in Anti-Atherosclerosis and Potential Therapeutic Targets for Nanomaterial-Derived Drug Formulations. Papers, record 37698552. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37698552

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Recent Advances in Anti-Atherosclerosis and Potential Therapeutic Targets for Nanomaterial-Derived Drug Formulations.
PubMed
Journal
Adv Sci (Weinh)
PubMed
Year
2023
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
27
iCite
Relative citation ratio, by iCite
2.8
iCite
Revised in PubMed
2024-10-01
PubMed

Authors12

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Xiao ZZhicheng
2Li YYi
3Xiong LLiyan
4Liao JJun
5Gao YYijun
6Luo YYunchun
7Wang YYun
8Chen TTing
9Yu DDahai
10Wang TTingfang
11Zhang CChuan
12Chen ZSZhe-Shenghttps://orcid.org/0000-0002-8289-097X

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
NanostructuresMajor topic
NanoparticlesMajor topic
AtherosclerosisMajor topic
Humans
Drug Delivery Systems
Drug Compounding

Grants3

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
20ZR1420000Natural Science Foundation of ShanghaiPubMed
21S21902100Science and Technology Support Project in Biomedical Field of Science and Technology Innovation Action Plan of Shanghai Science and Technology CommissionPubMed
2021-HSD-8-6-001Baoshan Zhaohui New Drug R & D and Transformation Functional PlatformPubMed

Source PubMed

Download CSV of grants

References164

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
131218557Folate Conjugated Double Liposomes Bearing Prednisolone and Methotrexate for Targeting Rheumatoid Arthritis.Pharm Res2019https://conductscience.org/library/papers/31218557PubMed
219435455Current advances in research and clinical applications of PLGA-based nanotechnology.Expert Rev Mol Diagn2009https://conductscience.org/library/papers/19435455PubMed
327562774Diverse macrophages polarization in tumor microenvironment.Arch Pharm Res2016https://conductscience.org/library/papers/27562774PubMed
430354259Impact of miRNA in Atherosclerosis.Arterioscler Thromb Vasc Biol2018https://conductscience.org/library/papers/30354259PubMed
535982578Use of acidic nanoparticles to rescue macrophage lysosomal dysfunction in atherosclerosis.Autophagy2023https://conductscience.org/library/papers/35982578PubMed
628011379Heart targeted nanoliposomal/nanoparticles drug delivery: An updated review.Biomed Pharmacother2017https://conductscience.org/library/papers/28011379PubMed
717848087Depletion of folate-receptor-positive macrophages leads to alleviation of symptoms and prolonged survival in two murine models of systemic lupus erythematosus.Mol Pharm2007https://conductscience.org/library/papers/17848087PubMed
824941020Fumagillin prodrug nanotherapy suppresses macrophage inflammatory response via endothelial nitric oxide.ACS Nano2014https://conductscience.org/library/papers/24941020PubMed
926706498Endothelial dysfunction and vascular disease - a 30th anniversary update.Acta Physiol (Oxf)2017https://conductscience.org/library/papers/26706498PubMed
1029751694Solubility of Cyclodextrins and Drug/Cyclodextrin Complexes.Molecules2018https://conductscience.org/library/papers/29751694PubMed
1129937375Chlamydia pneumoniae Hijacks a Host Autoregulatory IL-1β Loop to Drive Foam Cell Formation and Accelerate Atherosclerosis.Cell Metab2018https://conductscience.org/library/papers/29937375PubMed
1229851288Pleiotropic effects of the hemostatic system.J Thromb Haemost2018https://conductscience.org/library/papers/29851288PubMed
1314707059Innate immune discrimination of apoptotic cells: repression of proinflammatory macrophage transcription is coupled directly to specific recognition.J Immunol2004https://conductscience.org/library/papers/14707059PubMed
1426757788Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9): a randomized, placebo-controlled Phase 2 study.Eur Heart J2016https://conductscience.org/library/papers/26757788PubMed
1531822793Efferocytosis in health and disease.Nat Rev Immunol2020https://conductscience.org/library/papers/31822793PubMed
1619754375Oxidative stress, endothelial dysfunction and atherosclerosis.Curr Pharm Des2009https://conductscience.org/library/papers/19754375PubMed
1715668126The mannose receptor: linking homeostasis and immunity through sugar recognition.Trends Immunol2005https://conductscience.org/library/papers/15668126PubMed
1835999079ROS responsive nanoparticles loaded with lipid-specific AIEgen for atherosclerosis-targeted diagnosis and bifunctional therapy.Biomaterials2022https://conductscience.org/library/papers/35999079PubMed
1924385509ATP-binding cassette transporters, atherosclerosis, and inflammation.Circ Res2014https://conductscience.org/library/papers/24385509PubMed
203475709Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia.Proc Natl Acad Sci U S A1987https://conductscience.org/library/papers/3475709PubMed

See all 164 referencesDownload CSV of references

Cited by14

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 27 citations.

PMIDTitleJournalYearIn PapersSource
42939558Irisin in Cardiovascular Health and Disease: A Review of Its Function as a Biomarker and Therapeutic Target in Atherosclerosis and Related Conditions.Curr Issues Mol Biol2026https://conductscience.org/library/papers/42939558PubMed
42608966Prodrug Strategies in Atherosclerosis: Targeted Delivery and Therapeutic Advances.Cardiovasc Ther2026https://conductscience.org/library/papers/42608966PubMed
42569353Nanozyme-based therapeutic strategies for traumatic brain injury.Int J Pharm X2026https://conductscience.org/library/papers/42569353PubMed
42093999Studies of chitosan-Prussian blue nanozyme in auditory protection: from cellular mechanisms to in vivo validation.Front Immunol2026https://conductscience.org/library/papers/42093999PubMed
41494239Nanotechnology for atherosclerotic plaque stabilisation: bridging innovation and clinical practice.EBioMedicine2026https://conductscience.org/library/papers/41494239PubMed
41137064Nano-therapeutics targeting the macrophage-based microenvironment in the treatment of atherosclerosis.J Transl Med2025https://conductscience.org/library/papers/41137064PubMed
40985304A Hypoxia-Responsive Single-Atom Sonozyme for Targeted Sonocatalytic Therapy in Alleviating Atherosclerotic Plaque.Adv Sci (Weinh)2025https://conductscience.org/library/papers/40985304PubMed
40896801Macrophage-Targeted Nanomedicine for the Treatment of Atherosclerosis.Int J Nanomedicine2025https://conductscience.org/library/papers/40896801PubMed
40546800Combined Oxaliplatin with 5-Fluorouracil for Effective Chemotherapy Against Gastric Cancer in Animal Model.Int J Nanomedicine2025https://conductscience.org/library/papers/40546800PubMed
40521521The Role of ROS in Atherosclerosis and ROS-Based Nanotherapeutics for Atherosclerosis: Atherosclerotic Lesion Targeting, ROS Scavenging, and ROS-Responsive Activity.ACS Omega2025https://conductscience.org/library/papers/40521521PubMed
39917726Biomimetic nanoparticles co-deliver hirudin and lumbrukinase to ameliorate thrombus and inflammation for atherosclerosis therapy.Asian J Pharm Sci2025https://conductscience.org/library/papers/39917726PubMed
39116306Minimally Invasive Injectable Gel for Local Immunotherapy of Liver and Gastric Cancer.Adv Sci (Weinh)2024https://conductscience.org/library/papers/39116306PubMed
39036340Biomedical applications of stimuli-responsive nanomaterials.MedComm (2020)2024https://conductscience.org/library/papers/39036340PubMed
37698552Recent Advances in Anti-Atherosclerosis and Potential Therapeutic Targets for Nanomaterial-Derived Drug Formulations.Adv Sci (Weinh)2023https://conductscience.org/library/papers/37698552PubMed

Download CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
IL63569PubTator's text mininghttps://conductscience.org/library/genes/3569NCBI Gene
PCSK9255738PubTator's text mininghttps://conductscience.org/library/genes/255738NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/37698552

GET https://conductscience.org/api/papers/v1/37698552/references?page=2